Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments. It’s Sanders’ latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies.
1d
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...
Bipartisan lawmakers grilled Novo Nordisk CEO Lars Fruergaard Jørgensen in a Senate hearing in an attempt to pick apart the ...
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback